Camrelizumab Plus Docetaxel and Cisplatin in Recurrent or Metastatic Oral Squamous Cell Carcinoma Patients
Status:
Recruiting
Trial end date:
2023-06-02
Target enrollment:
Participant gender:
Summary
the purpose of this study is to assess the efficacy and safety of camrelizumab plus Docetaxel
and Cisplatin as First-line Therapy in Recurrent or Metastatic Oral Squamous Cell Carcinoma
Patients
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University